Liquidia Technologies Inc (LQDA)
NASDAQ:LQDA
Earnings Data
Report Date
May 07, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.37Last Year’s EPS
-0.45Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and clear evidence of rapid, profitable scale: robust Q4 sales growth, consecutive profitable quarters, meaningful cash generation, accelerating patient starts and prescriber adoption, and a pipeline of label- and market-expanding studies including a next-generation product. Risks highlighted include unresolved litigation, modest expected gross-to-net pressure as access expands, distributor inventory timing variability, and ongoing competitive entrants (oral agents and alternate inhaler formats). Management presented confident mitigation plans (expanded sales force, clinical transition studies, L606 development) and indicated operational cash funding for trials.Company Guidance
Strong Revenue and Rapid Quarter-over-Quarter Growth
Full-year 2025 YUTREPIA net product sales of $148.3M; Q4 2025 sales of $90.1M. Management reported Q4 growth versus Q3 of 2025 at ~74% (also referenced as ~80% QoQ increase in commentary).
Profitability and Cash Generation
Q4 2025 non-GAAP adjusted EBITDA of $27.3M and net income of $14.6M. Company generated $33M positive operating cash flow in Q4 and ended the year with ~$190.7M in cash and cash equivalents.
Rapid Commercial Launch and Patient Momentum
Since launch (9 months) >3,600 unique patient referrals and therapy shipped for >2,900 patients (through Feb 28, 2026). Patient starts composition: ~75% prostacyclin-naive and ~25% transitions.
Market Share Gains in Inhaled Treprostinil
Company estimates inhaled treprostinil quarter revenue was ~ $550M in Q4 and reports its revenue share grew from ~10% in Q3 2025 to ~17% in Q4 2025, indicating meaningful QoQ share gains and capturing disproportionate new patient starts.
High Prescriber Engagement and Pull-Through
Total prescribers increased to ~860; ~25% of clinicians have referred 5+ patients. Prescription-to-patient start conversion (pull-through) reported above 85%.
Clinical Differentiation and Evidence Generation
Management emphasized YUTREPIA's differentiated profile (deep-lung delivery, low-effort device, wide dose range), SENSE/ASCENT data showing tolerability and ability to dose 2–4x prior standards without cough exacerbation, and plans to initiate multiple new studies (transition studies, sotatercept adjunctive studies, PH-COPD, systemic sclerosis–associated Raynaud's phenomenon).
Strategic Growth Plans and Next-Generation Program
Company plans to expand commercial team by ~1/3, pursue label- and market-expanding studies, initiate a pivotal study for next-generation L606 (liposomal, twice-daily formulation) with enrollment expected in upcoming quarters, and targets a path to a $1B franchise by 2027.
LQDA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LQDA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 05, 2026 | $34.38 | $34.52 | +0.41% |
Nov 03, 2025 | $24.36 | $25.22 | +3.53% |
Aug 12, 2025 | $21.20 | $24.10 | +13.68% |
May 08, 2025 | $15.53 | $15.35 | -1.16% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Liquidia Technologies Inc (LQDA) report earnings?
Liquidia Technologies Inc (LQDA) is schdueled to report earning on May 07, 2026, TBA (Confirmed).
What is Liquidia Technologies Inc (LQDA) earnings time?
Liquidia Technologies Inc (LQDA) earnings time is at May 07, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LQDA EPS forecast?
LQDA EPS forecast for the fiscal quarter 2026 (Q1) is 0.37.